Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.Uncontrolled hyperlipidemia has been associated with serious cardiovascular events.  After initial approval, utilization of PCSK9 inhibitors remained low, possibly due to cost or overly restrictive coverage criteria. 
PCSK9
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.Uncontrolled hyperlipidemia has been associated with serious cardiovascular events.  After initial approval, utilization of PCSK9 inhibitors remained low, possibly due to cost or overly restrictive coverage criteria. 
PCSK9
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.Uncontrolled hyperlipidemia has been associated with serious cardiovascular events.  After initial approval, utilization of PCSK9 inhibitors remained low, possibly due to cost or overly restrictive coverage criteria. 
PCSK9
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.Uncontrolled hyperlipidemia has been associated with serious cardiovascular events.  After initial approval, utilization of PCSK9 inhibitors remained low, possibly due to cost or overly restrictive coverage criteria. 
PCSK9
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.Uncontrolled hyperlipidemia has been associated with serious cardiovascular events.  After initial approval, utilization of PCSK9 inhibitors remained low, possibly due to cost or overly restrictive coverage criteria. 
PCSK9